TREATMENT OF &lt;em&gt;BRAF&lt;/em&gt;&lt;sup&gt;V600E&lt;/sup&gt; POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT

Никифорович, П. А.; Румянцев, П. О.; Sleptsov, Ilya; Устинова, Т. В.; Слащук, К. Ю.; Vorobyev, S. L.; Serzhenko, Sergey S.; Абросимов, А. Ю.; Кудрявцева, А. В.; Semenov, Arseny; Chernikov, Roman; Поляков, А. П.; Феденко, А. А.; Болотина, Л. В.; Пайчадзе, А. А.; Трушин, А. Ю.; Каприн, А. Д.; Захарова, Г. С.

doi:10.21294/1814-4861-2020-19-5-131-144

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…• Паллиативная химиотерапия рекомендована в случаях отсутствия генетических мишеней для использования таргетной терапии. С паллиативной целью рекомендуется применять следующие режимы химиотерапии: паклитаксел** 50 мг / м 2 + карбоплатин** AUC 2 в/в еженедельно или паклитаксел** 30-60 мг/м2 в/в кап, еженедельно или паклитаксел** 175 мг / м 2 + карбоплатин** AUC 5-6 в/в 1 раз в 3 недели или #доцетаксел** 60 мг/м2 + доксорубицин** 60 мг / м 2 в/в раз в 3-4 недели до неприемлемой токсичности или #доцетаксел** 20 мг/ м2 + доксорубицин** 20 мг / м 2 в/в еженедельно или #цисплатин** 25 мг/м2 в/в кап, еженедельно до неприемлемой токсичности или доксорубицин** 60 мг / м 2 в/ в раз в 3 недели или доксорубицин** 20 мг / м 2 в/в еженедельно [55][56][57][58][59][60][61][62][63][64].…”

Section: уровень убедительности рекомендаций -с (уровень достоверност...unclassified

Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Section: уровень убедительности рекомендаций -с (уровень достоверност...unclassified

Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Targeted therapy of anaplastic thyroid cancer

Никифорович

Поляков

Sleptsov

et al. 2023

Opuholi golovy i šei

View full text Add to dashboard Cite

Introduction. Anaplastic thyroid cancer (ATC) is a very rare malignant tumor of the thyroid comprising 1–2 % of all thyroid cancers. In this pathology, response rate for standard systemic therapy is less than 15 %, and long-term results remain unsatisfactory. Additionally, there are no data conclusively showing that cytotoxic chemotherapy improves survival or quality of life in patients with ATC.Aim. To improve the results of treatment of patients with ATC through evaluation of the effectiveness of targeted therapy in cases of BRAFV600E mutation.Materials and methods. The multicenter prospective study included 29 patients with ATC IVB–C, T4a–bN1a–bM0–1. The patients were divided into 2 groups. The Group 1 (control) included 15 patients with resectable / nonresectable, metastatic / nonmetastatic ATC (without BRAFV600E mutation), stages IVB–C who received standard types of treatment (surgical intervention, radiation, and chemotherapy). The Group 2 consisted of 14 patients with nonresectable or metastatic ATC, stages IVB–C, who received combination therapy (surgical intervention, radiation, and chemotherapy) with inclusion of inhibitors of BRAF dabrafenib and trametinib in neoadjuvant and adjuvant regimens.Results. The study showed the effectiveness of targeted therapy with inhibitors of BRAF mutations in treatment of locally advanced non-operable metastatic ATC with BRAFV600E mutation. Overall response (complete response + partial response) in the Group 1 was 0 %, in the Group 2 it was 64 %. Therefore, treatment scheme dabrafenib + trametinib is a prmising approach to combination targeted therapy in patients with ATC and BRAFV600E mutation. Conclusion. Dabrafenib + trametinib is a promising combination targeted therapy option for patients with ATC with a BRAFV600 mutation demonstrates a high overall response rate, a prolonged duration of response, and an increase in survival rates with controlled toxicity.

show abstract

Anaplastic thyroid cancer: current capabilities of an oncologist

Pylev

Романов

Ласунин

et al. 2023

Opuholi golovy i šei

View full text Add to dashboard Cite

Continuous development of oncology as a science in the last decades and years led to noticeable improvement in treatment outcomes for patients with various malignant tumors. Diagnostics, surgery, radiotherapy significantly contributed to this improvement, however they cannot be compared to the progress achieved through advancements in our knowledge of genetic structure of tumors and subsequent advancements in pharmacology which allowed to achieve qualitatively better survival in oncological patients. These advancements did not leave out such a serious and highly lethal, though fortunately rare, disease as anaplastic thyroid cancer. This article is dedicated to the possibilities of using checkpoint inhibitors in treatment of this pathology to increase expected life span of the patients.

show abstract

TREATMENT OF <em>BRAF</em><sup>V600E</sup> POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT

Cited by 4 publications

References 23 publications

Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients

Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients

Targeted therapy of anaplastic thyroid cancer

Anaplastic thyroid cancer: current capabilities of an oncologist

Contact Info

Product

Resources

About